Education
About Us
Working with TipRanks
Follow Us
STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Top Page
STRATEC Biomedical
(XETRA:SBS)
Select Model
Select Model
Rating:60Neutral
Price Target:
€23.00
▲(5.99% Upside)
STRATEC Biomedical's overall stock score reflects a combination of mixed financial performance, bearish technical indicators, and reasonable valuation. The earnings call highlights both achievements and challenges, with supply chain issues and margin declines being significant concerns. The stock's valuation and dividend yield provide some support, but operational and market challenges weigh on the overall score.
STRATEC Biomedical (SBS) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€270.47M
Dividend Yield2.76%
Average Volume (3M)15.55K
Price to Earnings (P/E)16.9
Beta (1Y)1.35
Revenue Growth-1.64%
EPS Growth22.60%
CountryDE
Employees1,462
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.13
Shares Outstanding12,157,841
10 Day Avg. Volume11,323
30 Day Avg. Volume15,548
Financial Highlights & Ratios
PEG Ratio4.75
Price to Book (P/B)1.49
Price to Sales (P/S)1.41
P/FCF Ratio11.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€33.00Price Target Upside52.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
STRATEC Biomedical Business Overview & Revenue Model
Company DescriptionStratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
How the Company Makes MoneySTRATEC Biomedical generates revenue through multiple streams, primarily by providing automated diagnostic systems and associated consumables to healthcare organizations and laboratories. The company earns money from the sales of its proprietary analyzers and instruments, which are often sold in partnership with major diagnostic companies that utilize STRATEC's technology in their own products. Additionally, STRATEC benefits from recurring revenue through the sale of consumables that are required for the operation of its diagnostic systems. The company also engages in long-term contracts and collaborations with partners, which can include joint development projects and technology licensing agreements, further contributing to its revenue. Overall, STRATEC's business model is built on providing high-quality, reliable solutions that enable its customers to improve diagnostic processes and patient outcomes.
STRATEC Biomedical Earnings Call Summary
Earnings Call Date:Nov 07, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 26, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook with both achievements and challenges. While there were positive developments in sales growth, partnership expansion, and financial optimization, significant challenges were faced due to supply chain disruptions, margin declines, and decreased net income.Q3-2025 Updates
Positive Updates
New CFO Appointment
Tanja Bucherl has been appointed as the new CFO, bringing a strong financial background and team spirit to the organization.
Positive Sales Growth
Sales increased by 2.5% at constant exchange rate, reaching EUR 175.6 million, despite supply chain disruptions.
Partnership Development
Material progress in the development of partnerships, including a new customer and significant upturn in development activities.
Successful Loan Acquisition
Closed a EUR 125 million syndicated loan to further optimize financing structure and provide flexibility for future development.
Negative Updates
Supply Chain Disruptions
Supply chain interruptions impacted sales, particularly in the immunoassay franchise, causing delivery shortfalls.
EBIT Margin Decline
Adjusted EBIT margin declined to 7.3% from 8.8% in the prior year, due to less favorable product mix and reduced share of high-margin sales.
Lower Sales in Q3
Sales in the third quarter declined by 3.4% at constant exchange rate, impacted by supply chain disruptions and softer momentum in Service parts and Consumable business.
Decreased Net Income
Adjusted net income decreased by 15.8% year-over-year to EUR 7.1 million, driven by increased tax rate and reduced gross margin.
Company Guidance
In the 2025 financial results call, Stratec provided guidance indicating a flat top-line expectation for the year, matching the previous year's figures on a constant currency basis. The company anticipates an adjusted EBIT margin between 10% and 12%, but expects to end towards the lower end of this range due to product mix and ongoing supply chain issues. Despite these challenges, Stratec confirmed a 2.5% sales increase at constant exchange rates, reaching EUR 175.6 million for the first nine months. The adjusted EBIT margin for this period was 7.3%, down from 8.8% the previous year, largely due to a decline in the gross margin from 27.4% to 25.8%. The company also anticipates a notable improvement in earnings dynamics and a better tax rate in Q4, which should result in a full-year tax rate significantly below the previous 26.5%. Additionally, a successful closing of a EUR 125 million syndicated loan was highlighted, enhancing financial flexibility. The company remains focused on cost discipline, inventory management, and executing its development and partnership strategies to support future growth.STRATEC Biomedical Financial Statement Overview
Summary
STRATEC Biomedical shows a mixed financial performance. While maintaining healthy margins and a stable capital structure, the company faces challenges with declining revenue and profitability, along with significant reductions in free cash flow. The reliance on debt financing and reduced returns on equity highlight potential risks.Income Statement
STRATEC Biomedical's income statement shows a mixed performance. The company has a stable gross profit margin of around 29.65% in TTM, indicating efficient production processes. However, the net profit margin has decreased to 6.22% in TTM, reflecting challenges in controlling costs or pricing strategies. Revenue has declined by 3.35% in TTM, suggesting potential market or competitive pressures. The EBIT and EBITDA margins are relatively healthy at 10.83% and 18.38%, respectively, but have shown a downward trend, indicating potential operational inefficiencies.65
Positive
Balance Sheet
The balance sheet of STRATEC Biomedical reflects moderate financial stability. The debt-to-equity ratio stands at 0.54 in TTM, which is manageable but indicates a reliance on debt financing. The return on equity has decreased to 6.23% in TTM, suggesting reduced profitability for shareholders. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets, indicating a solid capital structure.70
Positive
Cash Flow
STRATEC Biomedical's cash flow statement reveals some concerns. The free cash flow has significantly decreased by 59.31% in TTM, highlighting potential liquidity issues. The operating cash flow to net income ratio is 0.54, indicating that cash generation from operations is not fully covering net income. The free cash flow to net income ratio is 0.63, suggesting that the company is not generating sufficient free cash flow relative to its net income, which could impact future investments or debt repayments.55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 257.14M | 257.62M | 270.41M | 274.63M | 287.33M | 250.10M |
| Gross Profit | 77.96M | 76.39M | 68.16M | 79.49M | 87.71M | 68.99M |
| EBITDA | 45.08M | 47.34M | 43.16M | 57.53M | 66.52M | 56.72M |
| Net Income | 14.70M | 16.02M | 15.37M | 29.22M | 39.96M | 25.18M |
Balance Sheet | ||||||
| Total Assets | 422.41M | 445.06M | 466.58M | 397.50M | 368.52M | 331.90M |
| Cash, Cash Equivalents and Short-Term Investments | 18.70M | 48.73M | 34.22M | 24.07M | 48.72M | 39.15M |
| Total Debt | 128.70M | 130.53M | 141.37M | 87.15M | 85.30M | 109.58M |
| Total Liabilities | 185.71M | 202.53M | 233.25M | 172.32M | 162.77M | 159.36M |
| Stockholders Equity | 236.70M | 242.53M | 233.33M | 225.18M | 205.76M | 172.54M |
Cash Flow | ||||||
| Free Cash Flow | 10.98M | 30.52M | 2.00M | -8.74M | 43.24M | 6.27M |
| Operating Cash Flow | 25.56M | 48.71M | 19.43M | 10.28M | 63.47M | 31.85M |
| Investing Cash Flow | -16.16M | -15.97M | -44.16M | -19.00M | -20.13M | -21.84M |
| Financing Cash Flow | -21.09M | -20.30M | 35.44M | -14.11M | -34.33M | 5.22M |
STRATEC Biomedical Technical Analysis
Negative
21.70
Price Trends
27.02
Negative
27.05
Negative
26.64
Negative
Market Momentum
-1.93
Positive
35.62
Neutral
40.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SBS, the sentiment is Negative. The current price of 21.7 is below the 20-day moving average (MA) of 24.41, below the 50-day MA of 27.02, and below the 200-day MA of 26.64, indicating a bearish trend. The MACD of -1.93 indicates Positive momentum. The RSI at 35.62 is Neutral, neither overbought nor oversold. The STOCH value of 40.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:SBS.
STRATEC Biomedical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | €1.20B | 10.60 | 8.22% | 2.97% | 2.14% | 6.69% | |
63 Neutral | €1.03B | 28.01 | 17.61% | 1.07% | 9.42% | 9.54% | |
60 Neutral | €270.47M | 16.88 | ― | 2.76% | -1.64% | 22.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €1.35B | -61.38 | ― | 0.11% | -18.82% | -113.85% | |
48 Neutral | €49.81M | -3.65 | -111.86% | ― | -4.90% | -69.80% |
* Healthcare Sector Average
DE:SBS
STRATEC Biomedical
21.70
-6.80
-23.85%
DE:BIO
Biotest
38.00
-3.60
-8.65%
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.41
-0.52
-17.75%
DE:DRW3
Draegerwerk AG & Co. KGaA
68.40
25.79
60.54%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
15.55
2.25
16.89%
DE:PUS
Pulsion Medical Systems
21.00
5.41
34.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.